# Bioequivalence of Fresenius Kabi USA, LLC Glucagon for SC Injection Compared to Glucagon for Injection (Bedford Laboratories)

> **NCT02086227** · PHASE1 · COMPLETED · sponsor: **Fresenius Kabi USA, LLC** · enrollment: 32 (actual)

## Conditions studied

- Hypoglycemia

## Interventions

- **DRUG:** Glucagon for Injection (Fresenius Kabi USA)
- **DRUG:** Glucagon for Injection (Bedford Laboratories)

## Key facts

- **NCT ID:** NCT02086227
- **Lead sponsor:** Fresenius Kabi USA, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2013-06
- **Final completion:** 2013-06
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2014-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02086227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02086227, "Bioequivalence of Fresenius Kabi USA, LLC Glucagon for SC Injection Compared to Glucagon for Injection (Bedford Laboratories)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02086227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*